Evofem's PHEXXI Hormone-Free Contraceptive Seeks Regulatory Approval in UAE Through Strategic Partnership
核心洞察
Pharma 1 Drug Store has submitted PHEXXI for marketing approval to the UAE Ministry of Health and Prevention, marking a key milestone in Evofem's international expansion strategy.
The FDA-approved hormone-free contraceptive gel represents the first locally-acting contraceptive that maintains vaginal pH to prevent sperm viability without systemic hormonal effects.
Commercial launch is targeted for Q1 2026 in the UAE, with Pharma 1 holding exclusive rights across multiple Middle Eastern markets including Kuwait, Saudi Arabia, and Qatar.
Evofem Biosciences has achieved a significant regulatory milestone as its partner Pharma 1 Drug Store LLC (搜索) filed an application with the United Arab Emirates Ministry of Health and Prevention seeking approval to commercialize PHEXXI, the company's FDA-approved hormone-free contraceptive gel.
The submission represents Evofem's first major step toward international commercialization of PHEXXI, which is currently the only locally-acting contraceptive gel approved by the U.S. Food and Drug Administration. The hormone-free formulation contains lactic acid, citric acid, and potassium bitartrate, working by maintaining the normal vaginal microbiome with a pH that is naturally inhospitable to sperm as well as certain viral and bacterial pathogens.
Strategic Partnership Drives Middle East Expansion
Pharma 1 Drug Store holds exclusive commercialization rights for PHEXXI across the Middle East, including the UAE, Kuwait, Saudi Arabia, Qatar and other countries in the licensed territory. The Emirati healthcare company will handle all aspects of distribution, sales and marketing, pharmacovigilance and commercial functions in these markets.
"With the submission to MOHAP now complete, we are developing our commercial strategy for PHEXXI in the UAE and look forward to launching this important product as quickly as possible following approval," said Abdulwahab Atfah, CEO of Pharma 1 Drug Store. "Market research indicates a growing demand for hormone-free, on demand contraception in the UAE and the surrounding region. We expect PHEXXI will be extremely well received among OB/GYNs and the women they serve."
Commercial Timeline and Revenue Projections
The companies are targeting a commercial launch in Q1 2026, with Pharma 1 expected to place a launch quantity order for PHEXXI in July 2025. This timeline would provide Evofem with an additional revenue stream from international sales beginning in mid-2025.
"This filing is an important milestone towards the commercialization of PHEXXI outside the U.S.," said Evofem CEO Saundra Pelletier. "We look forward to expanding and diversifying our revenue stream with PHEXXI sales to Pharma 1 for the UAE beginning in July 2025 to support the product launch in the UAE and provide Emirati women with access to hormone-free, non-systemic birth control that they control and use on-demand, only when needed."
Unique Mechanism of Action
PHEXXI's distinctive approach to contraception involves application zero-to-60 minutes before intercourse using a pre-filled applicator. Unlike hormonal contraceptives that work systemically, PHEXXI maintains local vaginal pH conditions that prevent sperm viability while preserving the natural vaginal microbiome.
The product addresses a specific unmet need for women seeking hormone-free contraceptive options that can be used on-demand rather than requiring daily administration or long-term commitment to hormonal methods.
Company Performance and Portfolio
Evofem reported its fourth consecutive year of net sales growth in 2024, generating revenue from two FDA-approved products. In addition to PHEXXI, the company markets SOLOSEC (secnidazole) 2g oral granules, an antibiotic indicated for bacterial vaginosis (搜索) in females 12 years and older, and trichomoniasis (搜索) in people 12 years and older. SOLOSEC provides complete therapy in a single dose and was relaunched by Evofem's commercial team in November 2024.
Pharma 1 Drug Store, established in 2019, has built expertise in the Gulf Cooperation Council healthcare market through its scientific approach and ability to adapt to the dynamic regional market conditions. The company currently serves as agents for multiple pharmaceutical companies with various commercial products and medications in process with the Ministry of Health and Prevention.